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ABSTRACT 
 
 
 
 
 
Endosialin (CD248) is a novel stromal cell surface receptor that has shown to play a 
 
role in both cancer and inflammation. Little is known about CD248’s structure, function 
 
and mechanism of action. 
 
 
 
 
Deletion mutants of CD248 were generated by overlapping fusion PCR, which were 
then stably-transfected into MG63 cells, detected by immunofluorescence staining and 
flow cytometry, and analysed using a growth curve assay. A Drosophila S2 cell 
expression system was used to produce recombinant CD248 protein. Hanging drop 
crystallisation technique was used to generate protein crystals. Western blotting was 
used to determine the phosphorylation state of MAPK ERK1/2 in mouse osteoblasts, 
post-induction with platelet-derived growth factor BB (PDGF-BB). 
 
 
 
Crystallisation screening of recombinant CD248 c-type lectin domain (CTLD) and 
ectodomain generated potential protein crystals for future x-ray crystallographic 
analysis. Growth curve analysis of CD248 cell surface-expressing MG63 cells 
demonstrated that the EGF repeat domain may be a key region of CD248 responsible 
for controlling the proliferation of MG63 cells. Primary osteoblasts from CD248-/- mice 
exhibited no response to stimulation with PDGF-BB, due to aberrant PDGF signal 
transduction in CD248-/- mice. This work provides a stepping stone to study and 
achieve a better understanding of CD248 structure, function and mechanism of action. 
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CHAPTER 1 - INTRODUCTION 
 
 
 
1.1 Background 
 
 
1.1.1 Cancer 
 
Cancer therapy has seen great improvements over the past few decades due mainly to 
recent advances in the areas of molecular medicine, proteomics, genomics and 
translational research. Progress in cancer genetics has also made it possible to identify 
genetic patterns that can be used in cancer diagnosis and prognosis. Despite this, cancer 
still remains the leading cause of death in developed countries accounting for 13% of all 
deaths each year. 
 
 
 
The development of a carcinoma is due to the accumulation of somatic mutations in the 
epithelial cell layer, however, the subsequent behaviour of a cancer cell is then 
regulated greatly by the surrounding microenvironment (Bhowmick et al. 2004). The 
stroma consists of a complex mixture of different cell types such as fibroblasts, 
lymphocytes, epithelial and endothelial cells along with extracellular matrix components. 
Molecular cross-talk between cancer cells and the stromal compartment can lead to an 
abnormal and activated phenotype, function and subsequent tumour progression. For 
example, it has been long recognised that tumours can induce a modified stroma through 
activated fibroblast populations, increased extracellular matrix 
protein expression, angiogenesis and increased lymphocyte populations. For this reason, 
this unique interplay between the tumour and its microenvironment has been a recent 
target of therapeutic strategies. 
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Of particular interest are fibroblasts which have been shown to be the most abundant cell 
type within the tumour stroma of many cancers, most notably breast and pancreatic 
cancer (Kalluri and Zeisberg 2006, Pietras and Ostman 2010). Not only do they actively 
define the structure of the stroma via the synthesis and remodelling of the extracellular 
matrix components (Gabbiani et al. 1971), but they also play a sentinel role in the 
immune system by conditioning the cellular and cytokine environment. Cancer- 
associated fibroblasts (CAFs) have been shown to induce the proliferation and growth 
of cancer by the overproduction of multiple factors including; extracellular matrix 
components, cytokines, chemokine’s, growth factors, prostanoids (PGE2), all of which 
affect cancer and immune cell behaviour (Bromwick et al. 2004). Despite their 
importance, fibroblast biology has lagged behind research into other cell types; due to 
its plastic and phenotypic and functional nature, as well as a distinct lack of selective 
markers for monitoring and isolating such cells. 
 
 
 
Cancer growth depends heavily on the formation of new blood vessels to meet metabolic 
and nutritional needs. For this reason, pericyte’s are another stromal cell type of interest 
for therapy. Pericyte’s are endothelial associated mural-derived cells that play an 
essential role in angiogenesis in terms of; stabilizing newly formed endothelial tubes, 
vascular splitting, sprouting, endothelial cell proliferation, migration and elongation 
(Franco et al. 2011). Recent studies have looked at the interactions between endothelial 
cells and pericyte’s which highlights the importance of targeting the stroma as a whole. 
These two cell types have a mutual relationship; whereby each other’s survival and 
proliferation is the result of bi-directional physical and chemical signalling. For 
example, pericyte’s have been shown to promote endothelial cell survival through the 
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induction of vascular endothelial growth factor-A (VEGF-A) and Bcl-W expression 
(Franco et al. 2011). (Bergers et al. 2003) have also shown that endothelial derived 
platelet derived growth factor (PDGF) induces VEGF expression in pericyte’s. Hence, 
targeting the stromal interactions that support malignant angiogenesis is of great interest 
for therapy. 
 
 
 
1.1.2 Inflammation 
 
Inflammatory disorders such as rheumatoid arthritis (RA) also represents a big problem 
that affects more than 2.9 million people in Europe alone (Duroux-Richard et al. 2011). 
RA is the most common inflammatory joint disorder characterised by synovial 
hyperplasia, ultimately leading to pain, inflammation, as well as bone and cartilage 
destruction if left untreated. Some of the most successful methods of combating such 
diseases include early diagnosis and improved therapeutic treatments. The functional 
parallels between cancer and inflammation have been known about since 1863, when 
Virchow reported that the origin of cancer derived from sites of ‘’lymphoreticular 
infiltrate’’. At the cellular level, both conditions are associated with the deposition of 
new extracellular matrix components and the activation of stromal cells, including 
fibroblasts, leukocytes and endothelial cells. 
 
 
 
Inflammatory diseases such as rheumatoid arthritis are typically characterised by an 
invasive and joint destructive synovia that exhibits hyperplasia, angiogenesis and 
inflammatory cell infiltrate leading to the development of lymphoid aggregate 
structures. Tissue resident stromal (TRS) cells are known to contribute to the 
progression and persistence of inflammation, via the increased production of pro- 
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inflammatory cytokines, matrix-degrading enzymes, growth factors, enhanced 
lymphocyte recruitment and reduced lymphocyte apoptosis. More specifically, TRS 
cells are able to determine the type and duration of leucocyte infiltration during acute 
inflammation, and are subsequently able to regulate the withdrawal of such survival 
signals and leucocyte apoptosis. 
 
 
 
Synovial fibroblasts have been shown to be an important stromal cell type in the 
progression of joint destruction and inflammation, and in the context of rheumatoid 
arthritis (RA), provide a good example of how stromal cells contribute to the 
persistence of chronic inflammation. Evidence suggests that RA synovial fibroblasts 
exert this effect through the altered production of survival signals such as type -1 
interferon (IFN-1) (Pilling et al. 1999) and the secretion of chemokine’s leading to the 
accumulation of lymphocyte populations within the synovial joint (Buckley et al. 2000). 
Activated synovial fibroblasts also secrete proinflammatory growth factors such as 
VEGF and placental growth factor (PIGF) that increase angiogenesis, synovial 
hyperplasia, leukocyte recruitment and inflammation (Yoo et al. 2008, Szekanecz et al. 
2010). Closely-associated pericyte’s are also thought to be involved in the development 
of arthritis and inflammation. These cell types have been shown to interact with the 
synovial stroma and in turn regulate the release of a variety of joint-damaging factors; 
PDGF, VEGF and transforming growth factor beta (TGFβ), (Franco et al. 2011). 
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1.1.2.2 Bone development (osteogenesis) 
 
Osteogenesis is a dynamic process governed by two types of specialised cells; 
osteoblasts (involved in bone formation) and osteoclasts (involved in bone resorption). 
During normal bone development, immature osteoblast cells are recruited to the site of 
bone formation (Maes et al. 2010), whereby they are kept in an immature state via 
PDGF signalling (Sanchez-Fernandez et al. 2008). Once they have undergone 
differentiation, mature osteoblasts become non-proliferative and upregulate type 1 
collagen (Liu et al. 1997).  In certain inflammatory disorders such as RA this process is 
perturbed, and more specifically is characterised by inflammation-induced focal bone 
loss. Within the inflammatory microenvironment, osteoclast differentiation is enhanced 
and osteoblast-mediated bone formation is inhibited leading to bone erosion and overall 
net weight loss. A number of studies have reported a lack of mature osteoblasts at the 
sites of focal bone erosion in RA (Gravallese et al. 1998) and murine inflammatory 
arthritis (Zwerina et al. 2006) and have linked perturbed osteoblast function to site- 
specific bone loss (Walsh et al. 2009). 
 
 
 
1.1.3 Endosialin (CD248) 
 
 
1.1.3.1 Introduction 
 
In an effort to better understand the biology and role of stromal cells in cancer and 
inflammation, cell surface marker proteins have been identified that are differentially 
expressed between normal and diseased tissue. A study in 1992 that screened for 
monoclonal antibodies that specifically recognised proteins on reactive fibroblasts, 
successfully identified Endosialin (CD248) as an antigen that was selectively expressed 
in vascular endothelial cells of malignant tumours (Rettig et al. 1992). Later in 2000, a 
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serial gene expression analysis (SAGE) study that involved comparing gene transcript 
levels on endothelial cells derived from blood vessels of normal and malignant 
colorectal tissues, also highlighted CD248 as the most upregulated in terms of gene 
expression (St Croix et al. 2000). Both these studies subsequently sparked a growing 
interest into the possibility of CD248 as a target for anti-angiogenesis therapies. 
 
 
 
CD248 has been mapped to chromosome 11 (11q13-qter) by serologic analysis of a 
panel of rodent-human somatic cell hybrids (Rettig et al. 1992), whereas the 
corresponding mouse gene has been mapped to chromosome 9 (Opavsky et al. 2001). In 
2001, the human CD248 gene was further characterised through molecular cloning of 
human CD248 cDNA (Christian et al. 2001). This study revealed that the CD248 gene 
consists of a 2274bp open reading frame that codes for a type I transmembrane 
glycoprotein with a molecular mass of around 80.9 kDa. Interestingly, the gene was 
found to be intronless and sequence alignment with its mammalian homologues has 
revealed a high level of sequence identity and conservation across vertebrates (Opavsky 
et al. 2001). 
 
 
 
The transcription initiation site is situated 17 bps upstream of the start codon (ATG). 
Opavsky et al. (2010) have demonstrated that CD248 gene transcription is upregulated 
in response to high cell density in vitro. This is thought to be mediated via the binding 
of transcription factor SP1 to the promoter region. In addition, a more recent study has 
reported an upregulation of CD248 gene expression during hypoxia (Ohradanova et al. 
2008). More specifically, they showed that Hypoxia-inducible factor 2 (HIF-2) activates 
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the endosialin promoter both directly and indirectly, through binding to the hypoxia- 
responsive element (HRE) or through Ets-1, respectively. 
 
 
 
1.1.3.2 Family members 
 
CD248 belongs to a family of C-type lectin-like transmembrane proteins implicated in 
tissue remodelling and repair. The word lectin is derived from the latin legere, meaning 
‘to select’ and is used to define proteins that have the ability to bind soluble 
carbohydrates or moiety’s as part of glycoproteins. The term CTL is used to distinguish 
a group of calcium-dependent lectin’s, from the calcium-independent forms. The C- 
type lectin (CTL) superfamily is a large well studied group of metazoan proteins with 
diverse functions such as adhesion and glycoprotein synthesis. The classification of such 
proteins was first outlined in a review published by Drickamer (1989) whereby he 
grouped CTLD-containing proteins into seven groups (I to VII) based on sequence 
analysis and domain organisation. Since then, the classification has been revised with 
the addition of seven new groups (Drickamer 1999, Drickamer and Fadden 2002). 
 
 
 
The Thrombomodulin family (Group XIV) consists of four-related proteins; endosialin 
(CD248), thrombomodulin (TBM), complement receptor protein (CD93) and C-type 
lectin domain family member 14A (Clec14A) (Figure 1A). All members are 
characterised by a CTLD protruding from the cell surface in addition to a sushi domain, 
epidermal growth factor repeats (EGF) and a highly glycosylated mucin-like region. 
Despite variation in overall amino acid identity between such family members, they 
maintain a high level of conservation in the globular domains and are all in some way 
involved in vascular biology. 
9 
 
 
 
 
Thrombomodulin is a well characterised molecule with a variety of known roles, 
including cell adhesion, in tumourigenesis and in the anticoagulant pathway (Hanly et al. 
2005), (Weiler and Isermann 2003), all mediated by different domains. For example, 
Wang et al (2000) have previously shown that EGF domains 5 and 6 are responsible for 
thrombin binding in the anticoagulant pathway. Whereas, another study has 
demonstrated that the CTLD of thrombomodulin plays an important role in preventing 
leukocytes from binding to the endothelium which in turn causes inflammation 
(Conway et al. 2002). 
 
 
 
 
CD93 was first identified by its role in activating phagocytosis in human monocytes via 
its interaction with complement factor C1q (Nepomuceno et al. 1999). CD93 is thought 
to function as a cell adhesion molecule (Dean et al. 2000). One such study that supports 
this hypothesis, reported the binding of the CTLD of CD93 to the endothelial cells 
(McGreal and Gasque 2002). 
 
 
 
Clec14A is the most recently discovered, and for that reason is the least studied member 
of the Thrombomodulin family. Two very recent studies have described Clec14A’s role 
in angiogenesis as a tumour endothelial marker (TEM), more specifically functioning in 
migration, tube formation and endothelial cell-cell adhesion via a CTLD-mediated 
interaction (Rho et al. 2011), (Mura et al. 2012). 
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Figure 1. CD248 is a member of the C-type lectin family 14. (A) Schematic diagram 
comparing CD248 with other members of the C-type lectin family 14. (Taken and adapted from 
Mura et al 2012). (B) Schematic diagram of CD248-specific domain organisation: The N- 
terminal signal leader peptide (SS, orange), the C-type lectin domain (C-LEC), the Sushi 
domain (S) and three EGF repeats (EGF) followed by the mucin-like region (MUCIN), the 
transmembrane section (TM) and the short cytoplasmic tail (CYT) (Modified from (Christian et 
al. 2001). 
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1.1.3.3 Structure 
 
CD248 is composed of several functional domains, none of which have yet been linked 
to any molecular functions. At the extreme N-terminus is a predicted short 20 amino 
acid (AA) leader peptide thought to assist translocation into the endoplasmic reticulum 
(Christian et al. 2001). Immediately downstream is a C-type calcium-dependant lectin 
(CTLD, 157 AA long). This domain has no known function and despite its 
classification, prediction software indicates that CD248 does not retain the sequences 
required for Ca2+ dependant ligand binding and has not been proven yet. Downstream 
of the CTLD is a sushi or complement control protein (CCP, 57 AA long). Multiple 
sushi domains are commonly found in proteins involved in regulation of the 
complement system, such as complement receptor type 1 (CR1/CD35) and factor H 
(Nangaku 1998). CD248 also contains three epidermal growth factor (EGF) repeats 
(156 AA) and a mucin-like region (269 AA) (Fig 1) of which is modified extensively by 
o-linked glycosylation (Christian et al 2001), a single transmembrane (48 AA) and a 
short cytoplasmic tail (51 AA), (Christian et al. 2001). The intracellular tail contains 
three potential phosphorylation sites and a PDZ-binding motif (4 conserved residues) at 
the extreme c terminus (according to PhophoSite). The latter have for a long time been 
recognised as protein-binding motifs that bind to intracellular proteins that contain 80- 
90 AA long PDZ domains and help organize small local protein complexes for signal 
transduction. Therefore, the PDZ-binding motif of CD248 may contribute to 
intracellular signalling pathways that lead to disease states. 
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1.1.3.4 Ligand interactions 
 
Few studies have looked at how expression is linked to its effects in cancer and 
inflammation. However, some in vitro studies suggest that the ectodomain of CD248 
may interact with particular extracellular matrix proteins including collagen 1, 4 and 
fibronectin (MacFadyen et al. 2005).  More recently, another group have given evidence 
for an interaction with a tumour derived ligand Mac-2 binding protein (Mac-2 BP), 
commonly linked to metastasis, which was shown to result in decreased tumour cell- 
myofibroblast adhesion (Becker et al. 2008). It is unlikely that the ectodomain binds 
sugars in a calcium-dependant manner due to the lack of conserved key amino acids in 
the CTLD, whereas the sushi, EGF and mucin-regions have all been shown to have the 
potential for calcium-independent binding in other receptors. Perhaps more 
interestingly, recently published data generated by the Claire Isackes lab have shown 
based on pericyte-EC co-culture assays that CD248-Fc binds to an EC-specific matrix 
protein (Simonavicius et al. 2012). In terms of intracellular ligand interactions, none 
have been found thus far. However, the cytoplasmic tail is bound to be important as this 
structure has been shown to be vital in RA and tumour growth mouse models (Maia et 
al. 2010, Maia et al. 2011). 
 
 
 
1.1.3.5 Expression 
 
CD248 exhibits a very restricted cellular expression profile. Originally there was some 
debate as to whether CD248 was also expressed by endothelial cells or closely- 
associated pericyte’s, after being defined as a tumour endothelial marker (TEM), (St 
Croix et al. 2000). MacFadyen et al. (2005) later demonstrated that CD248 was in fact 
expressed by endothelial-associated pericyte’s, not the endothelial cells themselves 
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using co-localisation with the pericyte marker NG2. MacFadyen et al. (2005) also 
reported the fibroblast-restricted distribution of CD248 by generating a panel of 
monoclonal antibodies towards isolated human fibroblasts. A recent study demonstrated 
that CD248 is predominantly expressed on perivascular and fibroblast-like synovial 
cells in the synovium from patients with psoriatric arthritis (PsA) and RA (Maia et al. 
 
2010). CD248 is also expressed on mesenchymal stem cells (MSCs) from the bone 
marrow (Bagley et al. 2009). MSCs are highly plastic cell type in nature, and have the 
ability to differentiate into adipocytes (fat), chondrocytes (muscle) or osteoblasts (bone). 
In fact, In silico mining of gene expression data. Su et al (2004) has shown that CD248 
is highly expressed on osteoblasts. In addition, CD248 expression has recently been 
described on naïve CD248+ T lymphocytes (Hardie et al. 2011). 
 
 
 
CD248 exhibits an interesting expression profile at the organ and tissue level. CD248 is 
expressed throughout a wide variety of tissues and organs during embryonic 
development not limited to the; heart, liver, brain, spleen, and neuroectoderm (Rupp et 
al. 2006, Lax et al. 2007). However, CD248 expression gets progressively less post- 
natally until absent on normal adult tissue. A variety of studies have confirmed high 
expression in a variety of different types of cancer, including sarcomas (Brady et al. 
2004), (MacFadyen et al. 2005), gliomas (Rettig et al. 1992), sarcomas (Huber et al. 
 
2006) and xenografts (Carson-Walter et al. 2009), specifically restricted to the stromal 
and perivascular cells. 
 
 
 
A more recent, less studied observation is the upregulation of CD248 on inflamed 
tissue. Maia et al. (2010) have recently reported high CD248 expression in synovial 
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tissue from RA and PsA patients, compared to healthy tissue. Even more recently Smith 
et al. (2011) demonstrated that CD248 is also upregulated in human chronic kidney 
disease (CKD) which was linked to known determinants of renal progression. 
 
 
 
1.1.3.6 Signalling 
 
The signalling mechanisms by which CD248 mediates its functions are controversial 
and largely unknown. The first study that provided evidence for the possible 
involvement of PDGF signalling was performed by (Christian et al. 2008), whereby 
they showed that CD248 knock-down in human fibroblasts leads to reduced migration 
in a PDGF-BB-dependant manner. Since then, a more recent study has described the 
mechanism by which CD248 regulates pericyte proliferation (Tomkowicz et al. 2010). 
It was reported that CD248 acts by the phosphorylation of the PDGF receptor, 
activation of MAP kinase ERK 1/2 and subsequent upregulation of c-fos transcription 
factor. The exact location at which CD248 intersects PDGF downstream signalling is 
still to be determined. However, this recent finding suggests that CD248 may recruit 
Src/PI-3 and c-fos pathways to exert its effect. The small cytoplasmic tail has no known 
kinase function but potential phosphorylation sites may interact with intracellular 
molecules in a direct or indirect-fashion. 
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Figure 2. Schematic representation of CD248-dependant signalling pathways and their 
proposed downstream functional effects. CD248 is required for PDG-signalling downstream 
of the PDGFR-B receptor: PDGF-B, secreted by activated endothelial or cancer cells, 
phosphorylates the PDGF Receptor, effectively upregulating downstream pathways involving 
Src/PI-3/ERK kinase, leading to the increased expression of c-fos which promotes proliferation. 
In addition, extracellular matrix proteins (Fibronectin and Collagen I/IV) bind to the CD248 
ectodomain leading to increased cellular migration via the upregulation of matric matrix 
matelleoprotease 9 (MMP9) and subsequent matrix degradation. An additional metastasis- 
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related ligand Mac-2 binding protein has also been described (taken and adapted from 
 
(Demoulin 2010)). 
 
 
 
 
1.1.4 CD248 in Cancer 
 
The functional significance of CD248 upregulation on stromal fibroblasts and pericyte’s 
in cancer is still largely unknown. But, functional studies in mice and in humans have 
provided evidence for an active role in tumour growth, invasiveness, metastasis and 
neovessel formation in a variety of cancer types; including breast, colon, renal, 
pancreatic, lung and sarcomas. For example, In vivo studies in mice show that CD248 is 
required for the progression of certain tumours; abdominal tumours that have been 
implanted into CD248-deficient mice exhibit a reduction in growth and metastasis as 
well as vasculature maturation defects (Figure 3). 
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Figure 3. The Effects of CD248 in Cancer. (A) and (B) Growth of tumours in 
immunocompetent mice. (C) Angiogenesis in abdominal tumors showing vessel number and 
size (D) Incidence of peritoneal carcinomatosis and liver metastasis (taken and adapted from 
(Nanda et al. 2006)). 
 
 
 
Recent studies have highlighted a number of functions at the cellular level. It has been 
reported that cells that overexpress CD248 exhibit increased cellular migration and cell- 
cell adhesion (Tomkowicz et al. 2007). Lax et al. (2007) have also shown that the 
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migration levels and proliferative capacity of mouse embryonic fibroblasts (MEF) 
 
derived from CD248-deficient mice are significantly lower than WT controls (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The Effect of CD248 on cellular migration and proliferation. (A) Migration levels 
of MEF derived from CD248 KO mice is considerably lower compared to WT control as 
assayed using a Dunn chamber. (B) Proliferative capacity of MEF derived from CD248 KO 
mice is significantly reduced relative to WT controls based on 3H uptake (taken and adapted 
from (Lax et al. 2010)). 
 
 
 
Other studies have reported similar functional effects, most notably cellular 
proliferation (Christian et al. 2008) migration and tube formation (Bagley et al. 2008a, 
Bagley et al. 2008b). 
 
 
 
It is not clear how these molecular functions result in their cellular effects, but as 
mentioned earlier, the finding that CD248 can bind to the extracellular matrix proteins 
(collagen 1, 4 and fibronectin), thereby upregulating matrix metalleoproteinase 9 
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(MMP9) that in turn mediates cell adhesion and cellular migration represents a possible 
explanation for CD248’s role in increased tumour growth and metastasis (via increased 
growth factor and cytokine release from the extracellular matrix, Figure 2). In addition, 
the expression, function and effects of CD248 suggest a role in early angiogenesis 
(Bagley et al. 2008b) and vessel maturation. The fact that CD248 expression is regulated 
by hypoxia also indicates a role in the formation and reorganization of the tumour 
stroma as well as blood vessels in areas of hypoxia and increased growth (Christian et 
al. 2008). 
 
 
 
1.1.5 CD248 in Inflammation 
 
The first indication that CD248 may also play a role in inflammation and the immune 
system was the reported upregulation of CD248 expression in stromal fibroblasts 
derived from the rheumatoid joint (MacFadyen et al. 2005) as well as on a specific 
subset of stromal cells involved in lymphoid tissue remodelling and repair, post 
infection (Lax et al. 2007). CD248 involvement has since been extended to other 
inflammatory disorders such as chronic kidney disease (CKD) and inflammatory bowel 
disease (IBD). The former study, reported the up regulation of CD248-expressing 
stromal cells and the correlation with known determinants of renal progression and 
disease outcome (Smith et al. 2011). The molecular mechanism by which CD248 causes 
its effects is unknown but is likely to be a result of increased cellular proliferation, 
migration, cytokine and chemokine factor release as seen in cancer progression, due to 
the fact that both disorders are characterised by an activated fibroblast population and 
mesenchymal cell involvement. In fact, more recent studies have shown that mice 
deficient in CD248 develop less severe arthritis and display characteristics such as 
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reduced synovial hyperplasia, leukocyte infiltration and cytokine levels (Maia et al. 
 
2010). 
 
 
 
 
 
 
 
1.1.6 CD248 is a Clinical Biomarker and Therapeutic Target. 
 
The fact that CD248 is upregulated in inflammation and cancer, in combination with a 
number of other desirable characteristics makes this receptor a prime candidate for the 
development of a novel molecular biomarker, for which there is a growing need. From a 
therapeutic perspective, the current state of knowledge suggests that the interaction 
between CD248-expressing stromal cells and extracellular matrix components 
represents a good strategy for inhibiting tumour progression. In addition, the fact that 
CD248 is a marker for tumour-associated pericyte’s makes it an attractive target for 
anti-angiogenic therapy, and the inhibition of proven fibroblast and pericyte functional 
characteristics such as proliferation and migration may offer therapeutic benefit, by 
interfering with the stromal contribution to inflammatory disease. There is currently a 
drive in the area of designing novel therapies which aim to inhibit CD248 in the form of 
potent blocking antibodies and small molecule inhibitors. There is an anti-CD248 
monoclonal antibody (MORAb-004) currently being developed and is undergoing phase 
1 and 2 clinical trials for the treatment of solid tumours (ClinicalTrials.gov identifier: 
NCT008470544), due to promising preclinical pharmacological results highlighting its 
usefulness as an anti-cancer drug. 
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1.2 The Aims 
 
The central theme of this research was to address the structure-function paradigm with 
the overall aim of investigating the molecular basis of CD248 function. Specifically, the 
first aim was to generate protein crystals of CD248 CTLD and complete extracellular 
domain in an effort to generate structural data. The second aim was to identify the 
growth characteristics of MG63 cells stably transfected with different CD248 mutant 
constructs in an effort to define key functional domains. The final aim was to provide a 
molecular mechanism for the observed effect of CD248 in osteoblast function and 
subsequent bone formation. 
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CHAPTER 2 - MATERIAL AND METHODS 
 
 
 
 
 
 
2.1 Material 
 
 
2.1.1 Bacterial strains, cell lines and plasmids 
 
DH5α E.coli cells were used as a host for constructing and propagating plasmids, 
 
whereas BL21 (DE3) E.coli host cells were used as a bacterial expression host. 
Drosophila Schneider 2 (S2) cells for protein production were obtained from Invitrogen 
(#R690-07). MG63 cells, a human osteosarcoma fibroblast-like cell line for protein 
expression studies were kindly given to me by Dr Debbie Hardie (Rheumatology 
Research Group, University of Birmingham). 
 
 
 
The mammalian expression vector for the human CD248 cDNA (pcDNA 3.1+) was 
purchased from Invitrogen. It contained both a c-myc and polyhistidine tag for 
purification and detection purposes. A Kozak sequence was introduced directly 
upstream of the start codon to allow the efficient translation of the recombinant protein. 
CD248 protein-coding regions were amplified from a plasmid previously generated in 
 
our group (Lax et al. 2010). For recombinant protein production in the Drosophila S2 
 
system, the pMT/BiP/V5-His expression plasmid (Invitrogen) was used which 
 
contained a metallothionein promoter (pMt) for heavy metals inducible expression. It 
 
also contained a V5 epitope, polyhistidine tag, biotinylation tag and a hygromycin 
 
resistance gene. 
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2.1.2 Primers 
 
Custom-designed primers were purchased from Invitrogen Life Technologies and 
prepared using TE buffer. 
 
 
 
2.1.3 Buffers, solutions and chemicals 
 
Agar plates: Agar poweder was added to LB medium to a final concentration of 1.5% 
and autoclaved. Solid LB-agar was then melted in a microwave and 100 µg/ml of 
ampicillin was added, before being poured into petri dishes and stored at 4 ° C. 
Agarose: Molecular Biology grade (Sigma-Aldrich #05066). 
 
Ampicillin: Working concentration 100 µg/ml (Sigma #A0166). Stored at -20˚C 
Cell Dissociation Buffer: Trypsin/EDTA 10X sterile filtered (Sigma #T4174). 
Coomassie Blue stain: 1.25 g Brilliant Blue, 250ml ddH20, 50ml acetic acid. 
Coomassie De-stain: 150ml Methanol, 300ml H20, and 50ml acetic acid. 
Drosophila S2 medium: SF900-SFMII medium (Invitrogen # 12658-019) containing 
 
10% heat inactivated foetal bovine serum (FBS) and hygromycin once transfected. 
DNA Ladder: 100bp (Invitrogen #15628-019). 
DNA Loading Buffer: 0.25% Bromophenol Blue, 0.25% xylene cyanol, 15% Ficol and 
ddH20. 
DNA stain: Hoescht stain (Molecular Probes #33258) 
Ethidium Bromide: used a t a final concentration of 0.5 µg/ml 
dNTPs: prepared 10mM stock DNTP SET - A,C,G,T (GE Healthcare #28-4065-62) 
 
FCS: (Invitrogen #10106-169) 
 
Freezing medium: Working concentration 10% DMSO in 90% FCS (Sigma #D8779). 
Fluorescence Activated Cell Sorting (FACs) buffer: 3% BSA in PBS 
25 
 
 
 
 
Geneticin (G418): Working concentration 500 ug/ml (Sigma #A1720). Stored at -20˚C 
 
High Imidizole buffer: 100mm Imidizole 20mM Na2PO4H20, 0.5M NaCl pH7. Low 
Imidizole Buffer: 10mM Imidizole, 20mM Na2PO4H20, 0.5M NaCl pH7. Mounting 
solution: Polyvinyl alcohol with DABCO® antifading gel (Sigma #10981). MG63 
Growth Medium: DMEM, 10% FCS. 
Ni-NTA magnetic Agarose Beads (Qiagen #30210). 
 
Non-enzymatic dissociation buffer: StemPro Accutase (Invitrogen #A11105-01). 
Optimem Reduced Serum Medium: (Invitrogen #2017) 
Paraformaldehyde (4%): Paraformaldehyde powder dissolved in PBS (Sigma #158127) 
PBS: Tablet dissolved in ddH20 (1 per 100ml), (Sigma #P4417). 
Refolding Buffer: 100 mM Tris pH 8.0, 400 mM L-arginine, 2 mM EDTA, 0.5 mM 
 
oxidized glutathione, 5 mM reduced glutathione and 0.1 mM PMSF with a final pH of 
 
8.3. 
 
Restriction enzymes: All purchased from NEB. 
 
SDS Running Buffer: Prepared from 10X Tris-Glycine-SDS ready-made buffer (Sigma 
 
#T7777). 
 
SyPro orange dye: (Invitrogen # 6650) 
 
TBE: 89mM Tris Base, 89mM Boric acid, 2mM EDTA. 
 
TBS-T: 100 mM Tris pH 7.5, 150 mM NaCl, 0.1 % Tween-20 
 
Triton-X-100: Sigma #T9284. 
 
T4 DNA ligase (5X): (NEB MO202S). 
 
Western Blot Transfer Buffer: 25 mM Tris pH 8.0, 192 mM glycine, 10 % methanol, 
ddH20. 
Velocity DNA Polymerase: (Bioline #21098). 
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2.1.4 Antibodies and kits 
 
Table 1. Antibodies 
 
Name Host Species Source # No. 
 
anti-human CD248 B1/35.1 Mouse Isacke Lab - 
 
anti-mouse p44/42 MPAK Rabbit eBioscience 4695 
 
anti-mouse phospho-p44/42 Rabbit eBioscience 9101 
 
MAPK 
 
anti-His (c-terminal) Mouse Invitrogen R930-CUS 
 
anti-mouse IgG HRP Rabbit Invitrogen 61-6520 
 
anti-mouse IgG Cy5 Goat Invitrogen A10524 
 
anti-mouse IgG FITC Rabbit Invitrogen 616511 
 
 
 
 
Dynabeads® M-280 Sheep Anti-Mouse IgG (Invitrogen #112-01D) 
 
ECL Plus Western Blotting Detection Reagent (GE Healthcare #RPN2132) 
Lipofectamine 2000 Transfection Reagent (Invitrogen #11668) 
Plasmid Mini Kit (QIAGEN #27104) 
Plasmid Maxi Kit (QIAGEN #12163) 
Nitrocellulose membrane (Amersham #RPN203G) 
QIAquick Gel Extraction Kit (QIAGEN #280704) 
X ray Film: Kodak X-OMAT (Sigma #F1149) 
27 
 
 
 
 
2.2 Methods 
 
 
2.2.1 Molecular Biology Techniques 
 
 
2.2.1.1 Polymerase Chain Reaction (PCR) and Overlapping PCR mutagenesis 
 
All PCR reactions were carried out using Velocity DNA polymerase according to the 
manufacturer's instructions. Full length cloning was conducted using the following 
reaction mixture; 20 pmol of each primer, 0.5 µg template DNA, 250 µM dNTPs, 5 x 
Hi-Fi Buffer, 3% DMSO and 1 unit of Velocity enzyme, made up to total volume of 50 
µL with PCR-grade water. The following standard cycling conditions were used; 1 
cycle at 98 ° C for 2 min, followed by 25 cycles at 98 ° C for 30 secs, 50-68 ° C for 30 
secs, and 72 ° C for 1 min 30 secs, and 1 final cycle at 72 ° C for 10 min. 
 
 
 
Overlapping PCR mutagenesis was conducted using a modified version of the protocol 
above. Two internal primers were designed for each desired domain deletion, one sense 
and the other antisense which contained a 30 bp overlapping sequence with one another, 
respectively (Table 2). Two separate PCR reactions were then carried out. PCR 1 used 
the 5’ end sense primer which introduced ATG start codon and EcoRI site, in 
combination with the reverse antisense primer. PCR 2 used the Forward internal primer 
with the 3’ antisense primer which introduced a TGA stop codon and XbaI site. This 
effectively generated two overlapping PCR products, which when verified (by agarose 
gel electrophoresis), purified (QIAgen kit) and subjected to a third round of PCR to 
anneal them together generated DNA coding the entire CD248 domain deletion insert. 
This was done in a 2-step manner; 1uL (20ng) of PCR1 and 2 were mixed together in 
combination with Velocity DNA polymerase, buffer, dNTPs, DMSO and water. One 
cycle of denaturation, annealing and extension was performed. The second step 
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involved (CD248 Full length 5’ and 3’ F and R) adding primers to a final volume of 50 
 
µL, and running a standard velocity PCR program. The final PCR fusion products were 
then analysed by agarose gel electrophoresis to verify they were of the expected size, 
digested with EcoRI and XbaI and ligated into the pcDNA 3.1 expression vector in a 
similar way to the wild-type construct. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Overlapping PCR mutagenesis of CD248. The example shown above is for the 
generation of CD248_Δ sushi. The 1st PCR reaction used a sense primer that was 
complementary to the N-terminus with a 5’ overhanging region, in combination with an 
antisense primer that was complementary to the beginning of the sushi domain. The 2nd PCR 
reaction used a sense primer that was complementary to the start of the EGF repeat domain and 
an antisense primer that was complementary to the C-terminus end of CD248. The 3rd PCR 
reaction used the overlapping PCR products from reaction 1 and 2 and the forward and reverse 
CD248 primers to amplify a fragment containing the full CD248 sequence minus the desired 
domain deletion. 
  
 
 
 
 
 
 
Table 2. Overlapping PCR mutagenesis oligonucleotide primers 
 
 
PCR 1 PCR2 PCR3 
 
 
 
Gene Insert Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
WT CD248 ------------------------ ------------------------ ------------------------- -------------------------- GCGAATTCGCC GCTCTAGATCA 
 -   - ACCATGCTGCTG CACGCTGGTTCT 
     CGCCTGTTGCTG GCAGGT 
CD248_Δ CTLD GCGAATTCGCC GCAGGCGGCAC CCCTGGGCTGCTGAG GCTCTAGATCA GCGAATTCGCC GCTCTAGATCA 
 ACCATGCTGCTG GGGGCTCAGCA CCCCGTGCCGCCTGC CACGCTGGTTCT ACCATGCTGCTG CACGCTGGTTCT 
 CGCCTGTTGCTG GC CAGTTTGGCTTCGAG GCAGGT CGCCTGTTGCTG GCAGGT 
   GGCGCCTGC    
CD248_Δ sushi GCGAATTCGCC CTCGAAGCCAA GACGGCTTACCTGTG GCTCTAGATCA GCGAATTCGCC GCTCTAGATCA 
 ACCATGCTGCTG ACTGGCACAGG CCAGTTTGGCTTCGA CACGCTGGTTCT ACCATGCTGCTG CACGCTGGTTCT 
 CGCCTGTTGCTG TA GACTGGCTGCAGCCT GCAGGT CGCCTGTTGCTG GCAGGT 
   GACAACGGG    
CD248_Δ EGF GCGAATTCGCC CACACAGCGGT CCAGCGGAGGATGA GCTCTAGATCA GCGAATTCGCC GCTCTAGATCA 
 ACCATGCTGCTG GCGGATCATCC TCCGCACCGCTGTGT CACGCTGGTTCT ACCATGCTGCTG CACGCTGGTTCT 
 CGCCTGTTGCTG TC GCCTGCAGGGGCCA GCAGGT CGCCTGTTGCTG GCAGGT 
   TGGGTGCCCAG    
CD248_Δ Muc GCGAATTCGCC CGTCCAGCCAC GCCTGGAAGGCCTTC GCTCTAGATCA GCGAATTCGCC GCTCTAGATCA 
 ACCATGCTGCTG CGTTGAAGGCC AACGGTGGCTGGAC CACGCTGGTTCT ACCATGCTGCTG CACGCTGGTTCT 
 CGCCTGTTGCTG TTC GACAGCCCTGGGGG GCAGGT CGCCTGTTGCTG GCAGGT 
   AGGCTGGTCTTG    
CD248_Δ CYT ------------------------ ------------------------ ------------------------ ------------------------ GCGAATTCGCC 
ACCATGCTGCTG 
GCTCTAGATCA 
CACGCTGGTTCT 
     CGCCTGTTGCTG GCAGGT 
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2.2.1.2 Agarose gel electrophoresis and gel purification 
 
1% agarose was prepared in Tris-Acetate-EDTA (TAE) buffer, cooled and 
supplemented with ethidium bromide (0.5 µg/ml) to visualise the DNA.  DNA samples 
were diluted in 5 X loading buffer prior to being loaded, separated at a constant voltage 
(80 V) and visualised using a UV box. Extraction and purification of DNA was carried 
using the Gel Extraction Kit (QIAGEN) according to the manufacturer’s instructions. 
 
 
 
2.2.1.3 Restriction enzyme digestion 
 
10 µg of purified DNA was incubated with 1-2 U of each restriction enzyme, 10 X 
Buffer, in a final volume of 40 µl at 37 ° C for 1.5-2 hours. The resultant digestion 
products were analysed and purified as described above. 
 
 
 
2.2.1.4 Bacteria transformation 
 
20 µl of competent cells were gently thawed on ice, mixed with 1µl of purified plasmid 
DNA and incubated on ice for a further 20 minutes, before being heat-shocked for 1 min 
at 42 ° C. The resultant mixture was then mixed with 250 µl of SOC medium for 1 hour 
in an orbital shaker at 37 ° C, of which 100 µl was spread onto an LB agar plate 
(containing 100 µg/ml ampicillin) and left overnight at 37 ° C. 
 
 
 
2.2.1.5 Plasmid DNA preparation 
 
An overnight culture (5 ml LB amp derived from a single colony of freshly-transformed 
E.coli DH5 alpha) was harvested and the plasmid DNA was purified using a Miniprep 
kit according to the manufacturer’s instructions. Maxiprep of plasmid DNA was 
conducted in a similar way using the QIAprep Maxiprep kit. 
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2.2.1.6 Colony screening 
 
Successful cloning was confirmed by colony PCR or restriction digest analysis prior to 
DNA sequencing. Colony PCR involved inoculating cells into a 20 µl standard PCR 
reaction. Test digests were conducted with 10 µl of purified miniprep plasmid DNA. 
PCR products and digestion products were analysed by agarose gel electrophoresis. 
 
 
 
2.2.1.7 DNA Sequencing 
 
Purified DNA samples were sent along with vector-specific primers to and performed 
by the Functional Genomics and Proteomics unit at the University of Birmingham 
utilising an ABI 3730 capillary sequencer. 
 
 
 
2.2.2 Recombinant protein production 
 
 
2.2.2.1 E.coli cells 
 
Recombinant protein was expressed as insoluble inclusion bodies in E.coli as routinely 
performed by our laboratory (Garboczi et al. 1992). Briefly, chemically-competent 
E.coli Bl21 (DE3) cells were transformed by standard heat shock method. Single 
colonies of transformed E.coli cells were then grown as starter cultures (LB medium 
supplemented with 100 µg/ml ampicillin) in an orbital shaker at 37° C before being 
transferred into 5L flask containing LB medium (supplemented with ampicillin) and 
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG). 
Overexpressed recombinant proteins were then purified and solubilised from inclusion 
bodies via sonication, homogenisation and dissolved in 8M Urea. The resulting 
inclusion bodies were analysed by SDS page prior to refolding. Chemical refolding of 
proteins was performed by the standard Garboczi method (Garboczi et al. 1992). 
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Briefly, refolding was initiated by pulse-step dilution of approximately 30mg of protein 
into 500mL refold buffer overnight at 4° C. The refold mixtures were then concentrated 
down to 10 mL using Amicon centrifugal filtration devices. 
 
 
 
2.2.2.2 Drosophila S2 cells 
 
S2 cells were grown at 27° C in T-25/ T-75 flasks in standard Drosophila medium, and 
supplemented with hygromycin once transfected. Cells were generally subcultured 
every 5 days (1:6), and seeded at a density of 1.2 x106/ mL. Transfection was performed 
 
by standard CalCl2 methods by the in-house technician Sarah Nichols. For large scale 
expression, S2 transfected cells were first subcultured into 125 mL of selective 
Schneider medium (500mL flask) supplemented with 0.05% Pluronic F-68 surfactant for 
4 days, prior to transfer into a final volume of 250mls in a 1L flask. Once the cells 
reached a density of ~3-5 x 106/ml, protein expression was then induced by the addition 
of CuSO4. After 3-5 days, the supernatant was collected via two rounds of 
centrifugation and stored in 0.02% Na Azide at 4° C. 
 
 
 
2.2.2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Recombinant proteins were separated on a 15% polyacrylamide gel, which was 
prepared as outlined in the table below (Table 3). The polymerised gel was then placed 
into the tank and filled with SDS running buffer. Approximately 10 µg of protein was 
mixed with reducing or non-reducing 5x SDS sample buffer boiled at 95 ° C for 5 
minutes and loaded alongside a molecular weight marker. Electrophoresis was 
performed at 120 V then increased to 180V once through the stacking gel. Gels were 
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then stained with Coomassie stain for 30-45 minutes with orbital shaking followed by 
 
De-stain solution for a further 30-45 minutes. 
 
 
 
 
Table 3. SDS-PAGE gel components for recombinant protein analysis 
 
 15% Separation 
 
(ml) 
Stacking (ml) 
30% Acrylamide 5.0 0.67 
ddH20 2.3 2.7 
Tris 
 
Buffer 
1M; pH 8.8 0.5 / 
1M; pH 6.8 / 2.5 
10 % SDS 0.1 0.04 
APS 0.1 0.04 
TEMED 0.004 0.004 
 
 
 
For electrophoretic separation prior to western blot analysis of cell lysates, cells in 1 
well of a 6-well plate were lysed directly in 100 µl of 1x Non-Reducing buffer. The 
lysates were then centrifuged for 3 min at 100g of which 20 µl of supernatant was 
loaded per lane (alongside pre-stained marker) of a 12% polyacrylamide gel (Table 4). 
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Table 4. SDS-PAGE gel components for cell lysate analysis 
 
 12% Separation 
 
(ml) 
5% Stacking 
 
(ml) 
30% Acrylamide 6 1.3 
ddH20 5.25 6.1 
Tris 
 
Buffer 
1.5M; pH 8.8 3.75 / 
0.5M; pH 6.8 / 2.5 
10 % SDS 0.15 0.2 
APS 0.075 0.1 
TEMED 0.003 0.002 
 
 
 
2.2.2.4 Western blotting 
 
Following electrophoresis, the separated protein bands were transferred to a 0.45µm 
PVDG nitrocellulose membrane using a BioRad Trans-well apparatus according to the 
manufacturer’s protocol. The blots were then blocked in 5% skimmed milk in 1 x Tris 
buffered saline tween (TBST) for 1 hour to block non-specific binding of antibody. 
 
 
 
For CD248 detection in Drosophila supernatant, the blot was stained with a mouse anti- 
His antibody (1:500) for 1 hour. The blot was subsequently washed in 3 stages with 1 x 
TBST before incubation with anti-mouse IgG HRP (1:1000) for 1 hour and 3 further 
washes. Proteins were visualised using enhanced chemiluminescence (ECL) kit and 
exposure to x-ray film ranging from 10 secs to 1 min. 
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For MAPK detection in osteoblast lysates, the blot was stained with anti-mouse p44/42 
 
MPAK or anti-mouse phosphor-p44/42 MAPK primary antibodies (1:2000) overnight at 
 
4° C on a rotating platform and detected with anti-mouse HRP (1:10,000) in a similar 
manner. 
 
 
 
2.2.2.5 Affinity chromatography 
 
1L of supernatant was dialyzed in 10X PBS buffer. The dialyzed supernatant was then 
transferred to a column pre-loaded with 1ml of Ni-NTA agarose beads overnight at 4° C. 
The next day the column was washed with 200ml of Low Imidazole-containing buffer 
to remove non-specifically bound proteins and eluted off the column with 7-8 ml of 
High Imidazole-containing buffer into 1ml fractions and analyzed by SDS-PAGE. 
 
 
 
2.2.2.6 Size-exclusion chromatography (SEC) 
 
SEC was performed using a Sepherose S200 column on an Akta FPLC machine 
(Amersham Biosciences) in combination with UNICORN software. In the first step 1 
litre of appropriate purification buffer was filter-sterilised and washed over the column. 
The s loop was then washed with 5ml of the same buffer followed by insertion of 7- 
10ml of pre-filtered protein sample onto the column at a maximum flow rate of 
 
2.5ml/min. The peak corresponding to the molecular weight of the protein was collected 
and analysed by SDS page. Quantification of protein was performed by measuring the 
optical density at 280 nm in combination with relevant absorption coefficients. 
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2.2.2.7 Buffer optimisation 
 
We used the thermofluor method as a high-throughput approach for identifying optimal 
protein buffer for purification and crystallization. The fluorescence thermal shift assay 
was performed as described before (Ericcson et al 2006). Each reaction contained 
protein, SyPro Orange in a 96 well plate. A melting curve program was run on the 
standard RT-PCR machine with a 1°C temperature increase every 30 seconds up to 
100°C. Computer software calculated the first derivative values (amplification plot) 
 
from raw fluorescence data to determine Tm (dissociation plot) A change in Tm of  > 
 
10°C was deemed as a significant difference that is likely to yield improved protein 
stability in solution. 
 
 
 
2.2.2.8 Crystallisation screening 
 
Preliminary crystallisation screens were set up using the automated Mosquito robot 
(TTP LabTech), via the hanging drop and sitting drop method. Protein was suspended 
over wells (96-well format) containing a variety of commercially purchased screens; 
Wizard I/II, JCSG+, SS, PEG R/X. Conditions yielding potential crystals were then 
followed up in large scale format, following negative control screens. Hanging and 
sitting drops were inspected for crystal formation after 3 days and on a weekly basis 
thereafter. 
 
 
 
2.2.4 Cell culture and analysis 
 
 
2.2.4.1 Culture conditions and passaging of cells 
 
The osteosarcoma MG63 cells were cultivated in complete fibroblast media, in a 
humidified incubator at 37 ° C with 10% CO2. 
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Adherent cells were passaged once 70-80% confluent. This was performed via 
incubation with trypsin/EDTA solution for 5 minutes, followed by centrifugation 
at1,000g for 5 min and resuspension in fresh medium with 33% conditioned medium 
before being seeded into new T75 flasks for continued culture at around 6x104 cells/ml. 
 
 
 
2.2.4.2 Storage of cells 
 
Adherent cells from a T75 flask were detached using Trypsin-EDTA, re-suspended in 
standard fibroblast medium, centrifuged at 1,000g for 5 min and then re-suspended in 3 
ml freezing medium before being aliquoted into 1 ml cryo-vials and stored at -80 ° C. 
Cryo-vials were later transferred into liquid nitrogen for long term storage. 
 
 
 
2.2.4.3 Transfection and generation of stably transfected cells 
 
All transfections were carried out using Lipofectamine 2000 reagent and procedure. 
MG63 Cells were plated at a cell density of 3-5 x 105 in a 6-well format in 2 ml of 
serum-free Optimem. The next day, for each cell of wells to be transfected, 2µg of 
endotoxin-free plasmid DNA was diluted into 250 µl of Optimem and 6-10 µl. 
Lipofectamine reagent was diluted into 250 µl of Optimem separately, before being 
mixed together at room temperature for 20 minutes to form DNA-Lipofectamine 
complexes. 500 µl of complex mixture was then added to each well in a drop wise 
manner, followed by incubation at 37 ° C. Stably transfected cells were then selected for 
 
48 hours post transfection using Geneticin selection media (500 µg/ml) for 2-4 weeks 
making sure to change the media every few days. 
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2.2.4.4 Positive isolation 
 
Magnetic beads coated with anti-mouse IgG were used to positively select cells of 
interest. After the Dynabeads were washed with PBS/BSA, harvested cells were 
labelled with CD248 monoclonal antibody B1/35.1 (IgG1 supernatant) on ice for 20 
minutes. In the second step labelled cells were bound with antibodies to magnetic beads 
by incubating 1ml of cells with 25 µl of Dynabead solution for 20 minutes at 4 ° C. In 
the final step, the bead-bound cells were isolated using the magnetic separator. The tube 
was placed into the magnetic separator for 2 minutes, supernatant was removed and the 
bound cells were washed multiple times to remove any residual unbound cells. 
Afterwards cells were re-suspended in complete fibroblast medium and seeded into T75 
flasks for continuous culture. 
 
 
 
2.2.4.5 Immunofluorescence and FACs analysis 
 
Adherent cells were plated at 3-5 x 104 cells per well in an 8-well chamber slide and 
cultured in fibroblast medium overnight. The next day, cells were washed with PBS and 
fixed with ice cold 3% paraformaldehyde (PFA) for 10 minutes. Cells were then 
blocked in 1% bovine serum albumin (BSA), PBS solution for 1 hour at room 
temperature to reduce non-specific antibody binding, before being incubated with the 
appropriate primary antibody for a further 1 hour. This was followed by 2-3 washes 
with PBS solution. Cells were labelled with CD248 monoclonal antibodies B1/35.1 
(1:3) and detected with incubation with anti-mouse IgG Cy5 (1:10,000) for 1 hour in the 
dark. After extensive washing in PBS, cells were incubated with the DNA stain 
(Hoechst) for 5 min and mounted with Dabco solution after brief rinses with PBS. Non- 
specific binding of antibodies was further controlled for by omitting the primary 
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antibody. Images were obtained using a LSM 510 confocal microscope (Zeiss, Welwyn 
 
Garden City, UK) equipped with a FITC and far-red filters. 
 
 
 
 
For FACs analysis, cells were harvested using a non-enzymatic dissociation buffer, 
counted and centrifuged at 100g for 5 minutes then re-suspended in FACs buffer at 1- 
5x105 cells/ml. Cell staining was performed in polystyrene round bottomed tubes in a 
 
final volume of 30-50 µl/ tube. Single-cell suspensions were incubated with CD248 
monoclonal antibody B1/35.1 (1:3) for 30-45 min on ice. Cells were then washed with 
FACs buffer by centrifugation at 100g for 5 minutes, re-suspended in anti-mouse Ig 
FITC (1:50) for 30 min on ice in the dark before being washed again, centrifuged and 
re-suspended in 500 µl of FACs buffer for analysis on a Cyan FACS analyser in 
conjunction with Summit software. Data were further analyzed using FlowJo Version 
7.2 software (TreeStar). 
 
 
 
 
2.2.4.6 Growth curve assay 
 
Cells were seeded in triplicate at a density of 1 x 104 cells per 24-well and cultured in 
complete fibroblast medium, under normal culturing conditions (37 ° C, 10% CO2). 
Cells were then harvested via trypsinization on days 1, 2, 3, 4, 5, 6, 7 and counted using 
a haemocytometer. The media in the remaining well was replaced with fresh media 
every 2-3 days. 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
MUTAGENESIS OF CD248 
41 
 
 
 
 
CHAPTER 3 - MUTAGENESIS OF CD248 
 
 
 
 
 
 
3.1 Introduction 
 
As mentioned earlier, CD248 has a known role in tumour growth, metastasis, wound 
repair and inflammation. Recent evidence suggests that CD248 may cause these effects 
by increasing the proliferation and migration of CD248-expressing stromal cells. 
Specifically, mouse embryonic fibroblasts (MEFs) derived from CD248 knockout mice 
have been reported to exhibit a significantly lower proliferative and migratory capacity 
compared to wild type MEFs (Lax et al. 2010). Despite such data, it is not yet known 
which region of the protein is critical for such observations. Therefore, this chapter 
describes the generation, characterisation and analysis of CD248 mutants in an effort to 
determine which structural domains may be responsible for these known effects. 
 
 
 
3.2 Results 
 
 
3.2.1 Construction and Transfection of CD248 or its mutants 
 
To construct WT and mutant CD248-containing mammalian expression vectors, the full 
length cDNA encoding human CD248 was amplified and subcloned into the EcoRI/XbaI 
sites of pcDNA 3.1+ plasmid (Methods section 2.2.1.1) to obtain CD248WT-pcDNA 3.1 
construct. The same CD248-containing plasmid was used for overlapping fusion PCR 
(Methods section 2.2.1.1) whereby specific domains were deleted and given the following 
names; CD248_Δ CTLD, CD248_Δ sushi, CD248_Δ EGF, CD248_Δ mucin, CD248_Δ 
cytoplasmic. A schematic representation of the CD248 gene illustrating the domains 
targeted for PCR amplification and mutagenesis can be seen in Figure 6 alongside the 
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corresponding products from the individual PCR reactions. The sizes of the products in 
Figure 6 are consistent with the expected fragment sizes, for example in an effort to 
generate CD248_Δ CTLD fragment, the 1st PCR reaction produced a ~ 100bp, the second 
produced a ~1800bp fragment, and the third fusion reaction produced a fragment of 
2000bp. The different CD248 mutant inserts were then subcloned into EcoRI/XbaI sites 
of pcDNA 3.1+ plasmid, maxiprepped, and fully sequenced to confirm successful 
mutagenesis and subsequent cloning (data not shown). 
  
 
 
 
 
 
 
 
43 
A B 
 
 
 
 
 
 
 
 
 
 
 
 
C D 
 
 
 
 
 
 
 
 
 
 
 
 
E F 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Generation and electrophoretic analysis of WT CD248 and mutant fusion products from  overlapping PCR-generated fragments by overlap 
extension PCR (described in detail in methods section). (A) amplification of full length CD248 in a single PCR reaction, (B) PCR1 and 2 generated a 100 bp and 
1700bp fragments, respectively, which were then fused to make CD248_Δ CTLD of 1800bp fragment, (C) PCR1 and 2 generated a 400 bp and 1600bp fragments, 
respectively which were fused to make CD248_Δ sushi 2kb fragment, (D) PCR1 and 2 generated a 900 bp and 1200bp fragments, respectively which were fused to 
make CD248_Δ EGF 2.1 kb fragment, (E) PCR1 and 2 generated a 1200 bp and 400 bp fragments, respectively which were fused to make CD248_Δ mucin 1.6 kb 
fragment, (F) amplification of full length CD248 minus the cytoplasmic tail in a single PCR reaction. 
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To generate CD248-expressing stable cells, myc-tagged plasmid DNA encoding wild- 
type or mutant CD248 were individually transfected into MG63 osteosarcoma cells 
(express no endogenous CD248). All transfections were carried out as described in 
methods section 2.2.4.3. Stably transfected cells were established 2-4 weeks later 
following antibiotic selection. Magnetic beads coated with anti-mouse IgG and anti- 
CD248 B1/35.1 antibody were then used to positively select for CD248-expressing cells 
as described in methods section 2.2.4.4. 
 
 
 
3.2.2 Expression and subcellular localization of CD248 or its mutants in MG63 cells 
Resulting stably transfected cells were then fixed in paraformaldehyde (3%) and 
analysed by immunofluorescence staining for CD248 and correct subcellular 
localisation. Untransfected MG63 cells were used as CD248-negative Controls. 
 
 
 
By confocal microscopy, the B1/35.1 anti-CD248 monoclonal antibody detected 
exogenous CD248 expressed by the MG63 transfected cells (Figure 8). However, the anti- 
myc antibody directed to the c-terminal myc tag was unable to detect such CD248 
expression. It can be seen from Figure 7 that CD248 is expressed at moderate levels in all 
of the transfected cells whilst no background staining was seen in the negatively 
transfected MG63 cells (Figure 7) and no antibody control (data not shown). 
 
 
 
The subcellular distribution of CD248 was not consistent across all stably transfected cell 
populations. The localisation of CD248 in CD248_Δ sushi, CD248_Δ EGF stably- 
expressing cells appeared to be predominantly cell surface staining, as well as some 
cytoplasmic staining (Figure 7). Whereas CD248 staining appeared to be predominantly 
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cytoplasmic with very little cell surface staining in the CD248_WT, CD248_Δ CTLD, 
CD248_Δ mucin, CD248_Δ cytoplasmic stably-expressing cells (Figure 7). The cytosolic 
staining was not uniformly spread but exhibited a granular pattern characteristic of that 
seen with the proteins associated with endoplasmic reticulum or Golgi vesicles. 
 
 
 
In addition, the percentage of CD248 cell surface expressing cells were analysed by flow 
cytometry (Figure 8). The method as outlined in Section 2.2.4.5 used the B1/35.1 anti- 
CD248 monoclonal antibody in an unconjugated fashion. It can be seen from Figure 9, 
that the CD248_Δ sushi, CD248_Δ EGF stably-expressing cells exhibited two peaks of 
fluorescence, populations of cells. In the CD248_Δ sushi cell line, the first peak 
comprised 58.7% of the cells. The second peak comprised 42.3% of the cells which 
represented the CD248-positive cell population (Figure 8).  Likewise, in the CD248_Δ 
EGF cell line, the second peak comprised 43.4% CD248-positive cells population (Figure 
8).   However,   the   CD248_WT,   CD248_Δ   CTLD,   CD248_Δ   mucin,   CD248_Δ 
 
cytoplasmic cell lines exhibited negligible shifts in fluorescence (Figure 8). 
  
Untransfected CD248 WT CD248 CTLD Δ 
DAPI/ CD248       
 
 
CD248 Sushi Δ CD248 EGF Δ CD248 CYT Δ 
 
 
Figure 7. Immunoflourescence analysis of myc-tagged CD248 in stably-transfected MG63 cells. myc-tagged CD248 was transfected into 
to MG63 cells using the Lipofectamine 2000 (Invitrogen). The cells were fixed with 3% paraformaldehyde 2-4 weeks post transfection 
following antibiotic selection and stained with B1/35.1 anti-CD248 antibody and detected with anti-mouse IgGCy5 secondary antibody. The 
nucleus (grey) was stained with Hoechst DNA stain. The cells were observed by confocal microscopy. All images were taken at 25X zoom 
factor. 46 
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Figure 8. Flow cytometry analysis of myc-tagged CD248 in stably-transfected MG63 cells. myc-tagged CD248 was transfected into to 
MG63 cells using the Lipofectamine 2000 (Invitrogen). Cells were harvested using a non-enzymatic dissociation buffer 2-4 weeks post 
transfection following antibiotic selection and stained with B1/35.1 anti-CD248 antibody and detected with anti-mouse IgG FITC secondary 
antibody. Fluorescence is indicated on the x-axis. 47 
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3.2.3 Overexpression of CD248_Δ sushi increases the growth rate of MG63 cells 
The CD248_Δ sushi, CD248_Δ EGF cell surface-expressing MG63 cells were then used 
in subsequent functional assays. Growth curve analysis was performed to determine the 
possible role of either of the sushi or EGF domains in the proliferation of MG63 cells. To 
determine the growth ability of each cell line, each cell population was analysed for cell 
number every day for a week, post-seeding into 24-well plates (Methods section 2.2.4.6) 
and subsequent growth curves were drawn (Figure 9). 
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Figure 9. Growth curves of untransfected, CD248_Δ sushi, CD248_Δ EGF-expressing MG63 
cells.  Each cell population was cultured in complete fibroblast medium and cell numbers were 
counted using a haemocytometer on respective days. Means of three observations. 
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The growth curve assay showed that the growth of cells did not differ significantly 
during the first 2-3 days. However, from day 4 on, the growth rate of CD248_Δ sushi 
cells significantly increased relative to untransfected cells and CD248_Δ EGF cells 
(Figure 9). Therefore, the overexpression of CD248_Δ sushi appeared to increase the 
growth rate of MG63 cells. 
 
 
 
3.3 Conclusions and Discussion 
 
This chapter aimed to describe the generation and characterisation of CD248 mutants in 
an effort to determine which structural domains may be responsible for these known 
effects. Some of the technical issues identified while performing this work will now be 
discussed 
 
 
 
The first step involved using an Overlapping extension PCR-based method in an effort 
to generate a variety of CD248 mutants whereby specific whole domains were deleted 
individually. Methods used for the fusion of two (or more) DNA fragments include 
conventional RE cloning and adaptors which is often tedious, time consuming and 
requires the introduction of unwanted sequences (Shevchuk et al. 2004). A quicker, 
more precise quicker alternative method is commonly known as overlap extension PCR. 
This method was used to successfully create precise deletion mutants with 100% 
sequence accuracy as evidenced by subsequent DNA sequencing of final plasmid DNA, 
but several technical points should be taken into consideration. First, it is important that 
the primers have very similar Tm values, which is vital for annealing and amplification 
within the final fusion PCR reaction (Kuwayama et al. 2002). Secondly, the third fusion 
PCR reaction should be performed with purified PCR products free from previous 
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primers, as these can inhibit the accuracy of such reaction. Once the mutant (and 
wildtype) CD248 genes were subcloned into the mammalian expression vector of 
choice, CD248-expressing stable MG63 cells were generated via a standard 
lipofectamine 2000 transfection method. The same technique has been done previously 
to generate WTCD248-expressing MG63 cells (Hardie et al. 2011), but never before 
with such mutants. 
 
 
 
Immunofluorescence staining of stably-transfected cells indicated that the subcellular 
distribution of CD248 was not consistent across all transfected cell populations. The 
localisation of CD248 in CD248_Δ sushi, CD248_Δ EGF cell surface-expressing MG63 
cells across the entire cell surface, whereas CD248 staining in CD248_WT, CD248_Δ 
CTLD, CD248_Δ mucin and CD248_Δ cytoplasmic stably-expressing cells was 
predominantly cytoplasmic, with very little cell surface expression. This observation of 
cell surface expression was confirmed during FACs analysis, by measuring the 
percentage of CD248 cell surface expressing cells within each population. This 
contradicts previous literature that CD248 is expressed predominantly at the cell surface 
in vitro (Rettig et al. 1992, Christian et al. 2001, Brady et al. 2004). But interestingly, this 
localization is similar to that seen for thrombomodulin following transfection, 
permeabilization and immunostaining of cultured cells (Teasdale et al. 1994). The 
cytoplasmic staining of CD248_WT, CD248_Δ CTLD, CD248_Δ mucin and CD248_Δ 
cytoplasmic stably-expressing cells could be explained by a number of possibilities. The 
most likely explanation is that the overexpression of exogenous CD248 or the myc tag at 
the c terminus may have caused aberrant accumulation of CD248 in intracellular secretory 
organelles.  In  terms  of  the  mutants,  the  deleted  sequence  (ie.  CTLD,  mucin  and 
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cytoplasmic tail) may be needed for transport from the ER and localization to the plasma 
membrane. Such intracellular expression may also represent an immature form as it is 
processed through the golgi, as previous literature has reported the presence of CD248 in 
recycling endosomes (Opavsky et al. 2001). 
 
 
 
In order to find out which domains were important for growth rate characteristics, it was 
important to use cells that expressed CD248 on the cell surface. For this reason, growth 
curve analysis was only performed on the CD248_Δ sushi, CD248_Δ EGF cell surface- 
expressing MG63 cells. Growth curve analysis demonstrated that the overexpression of 
CD248_Δ sushi increased the growth rate of MG63 cells. This data matched previous 
findings within the lab that overexpression of wild-type CD248 increased the 
proliferation of MG63 cells (Hardie et al 2011). On the other hand, overexpression of 
CD248_Δ sushi did not increase the growth rate of such cells. This data suggests that the 
EGF repeat domain may be the key region of CD248 responsible for controlling the 
proliferation of MG63 cells, whereas the sushi domain is not. 
 
 
 
However, it is important to be aware of the potential limitations of such techniques. 
Firstly, the MG63 cell type may not be the best model system for studying CD248 
function, and fibroblasts and perciytes might represent a more physiologically relevant 
system. In addition, simple growth curve analysis may not be the best functional assay to 
study cell proliferation, and assays including thymidine incorporation and BrdU readout 
may represent more accurate experiments. For example, these are commonly performed 
over a range of cell densities, which is important as CD248 has been shown to be effected 
by cell density (Opavsky et al 2001). 
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CHAPTER 4 – CRYSTALLISATION OF CD248 
 
 
 
 
 
 
4.1 Introduction 
 
The C-type lectin (CTL) superfamily is a well-studied group of metazoan proteins, both 
structurally and functionally. They have been shown to have diverse functions such as 
adhesion and glycoprotein synthesis. The Group XIV Thrombomodulin subgroup have 
also been well studied from a functional perspective, however, there is a distinct lack of 
knowledge concerning the 3 dimensional structure of type XIV proteins, with only the 
partial crystal structure of thrombomodulin having been resolved in complex with 
thrombin (Fuentes-Prior et al. 2000). 
 
 
 
Numerous studies have reported the upregulation of CD248 and highlighted the role of 
CD248-expressing stromal cells within the tumour microenvironment and inflammatory 
microenvironment. Both scenarios are characterised by an activated stromal compartment 
and mesenchymal cell involvement. At the cellular level, CD248 has been linked to 
cellular effects including proliferation, adhesion and migration of stromal cells (Christian 
et al. 2008, Tomkowicz et al. 2007). Recent publications suggest that ectodomain 
interactions with extracellular matrix proteins may explain such functional effects 
(Tomkowicz et al. 2007). 
 
 
 
Despite these studies, the structural and molecular basis of CD248 function is still 
unclear. Therefore, this chapter describes the recombinant expression of its entire 
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extracellular domain (as well as CTLD alone), purification and crystallisation of 
 
CD248, for future crystallographic analysis of the receptor. 
 
 
 
 
4.2 Results 
 
 
4.2.1 Production and crystallisation of CD248 c-type lectin domain (CTLD) 
 
This section describes the production of soluble CD248 CTLD in quantities sufficient 
for use in x-ray crystallographic studies. 
 
 
 
CD248 was originally expressed in E.coli BL21 (DE3) cells in the form of inclusion 
bodies (Figure 10), which were then purified and solubilized in 8M Urea buffer. The 
CD248CTLD-containing bacterial expression vector was previously generated in the lab 
(by Sarah Nichols, PEF facility). CTLD protein was expressed at a relatively high level 
and purity in the inclusion bodies, seen as a single protein band ~16 kDa on the SDS 
page gel (Figure 10A). The inclusion bodies were then subjected to standard chemical 
refolding methods (Methods section 2.2.2.1) and purified by gel filtration 
chromatography (into 20 mM MES and 50 mM NaCl) as a single peak on the elution 
profile (Figure 10B). Subsequent analysis of pooled elution peak fractions on an SDS 
page gel identified a higher single protein band of an incorrect size (~ 30 kDa) suggesting 
that the CTLD domain may not be susceptible to in vitro refolding techniques. Despite 
considerable efforts to produce soluble homogenous CD248 CTLD in a bacterial expression 
system, these attempts were largely unsuccessful as the yields 
acquired from this method were too low and judged inadequate for downstream 
structural studies. 
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Figure 10. Expression, purification and SDS PAGE analysis of bacterially-expressed CD248 CTLD (A) SDS PAGE analysis of inclusion body 
preparation CD248 C-type lectin domain, under reducing and non-reducing conditions (B) size exclusion chromatography elution profile for CD248 
CTLD after FPLC using S200 column. (C) SDS PAGE analysis of FPLC elution peak, under reducing and non-reducing conditions (predicted MW = 16 
kDa). 
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Therefore, the CD248 CTLD was then expressed in an insect expression system using 
S2 cells as an alternative in an effort to produce soluble CD248 CTLD in quantities 
sufficient for use in structural studies. The CTLD expression construct was designed 
and generated by cloning the coding region of the gene into the pMT/BiP/V5-His 
expression vector, which was then used to transfect Drosophila S2 cells using calcium 
phosphate transfection method and create stable cell lines (Methods section 2.2.2.2) 
(Both conducted by Sarah Nichols, PEF facility). Transfection, expression and correct 
protein conformation were confirmed by western blotting the supernatant with an anti- 
His antibody (Figure 11A). The fact that CD248 CTLD was detected and displayed a shift 
in molecular weight between reducing and non-reducing conditions at 3-4 days post- 
transfection suggested correct protein conformation and disulphide bond pairing. The 
supernatant was then dialyzed into appropriate buffer prior to purification of his-tagged 
proteins by Ni-NTA chromatography (Methods section 2.2.2.5). Following NI-NTA 
chromatography, the purified and concentrated protein was analysed by SDS-PAGE 
(Figure 11B). It can be seen from Figure 11B, that the protein sample was of high 
purity, migrated at the expected size (~16 kDa) with very few contaminants following 
purification and obtained estimated yields of ~8-12 mg’s/ Litre of supernatant. The 
Drosophila system produced higher yields of protein at required purity, adequate 
enough for crystallization purposes, without the need for further purification procedures. 
CTLD CD248 protein was purified into a standard Tris NaCl pH 8.0 buffer. 
 
 
 
Drosophila-expressed protein was used to set up crystallisation trials. Initial CTLD 
crystallization screens were attempted at 5mg/ml, but unfortunately yielded no crystal 
hits and also experienced protein stability issues at concentrations greater than 5 mg/ml. 
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In order to obtain high enough protein concentrations for successful crystallization (ie. 
above 5 mg/ ml), an optimum buffer in which the protein is stable and soluble was 
required. For this reason, a thermal shift screening assay was conducted (with the help 
of Dr Timothy Knowles, Figure 12C). Buffer optimization involved choosing a buffer 
which increases the melting temperature (Tm) of your protein. It can be seen from 
Figure 12C and D that a number of different buffers produced a shift in melting 
temperature compared to the standard Tris Nacl buffer. For example, 50mM MES 100 
mM Cacl2 had melting temperatures of  65°C. CD248 CTLD protein was re-purified 
into 50 mM MES 100 mM CalCl2 buffer due to the predicted calcium binding nature of 
CTLDs, which subsequently allowed crystallization trials to be set up at higher 
concentrations of 11.6 mg/ml. Initially the hanging drop technique yielded 13 potential 
crystal hits. However, 11 out of 13 of these turned out to be salt crystals after negative 
controls were performed, which left 2 conditions that were potentially yielding protein 
crystals (2 of which can be seen in Figure 15, B and C); Structure screen condition # 2.6 
 
0.1M Nickel chloride hexahydrate, Tris pH 8.5, 1M Lithium Sulphate, and 0.01M Zinc 
sulphate heptahydrate, MES pH 6.5, 25% v/v PEG-MME 550. 
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Figure 11. Expression, purification and SDS PAGE analysis of Drosophila-expressed CD248 CTLD (a): Western blot detection of CD248 
CTLD expression under reducing and non-reducing conditions, at 72 h and 96 h post- induction, using anti-His antibody SDS PAGE analysis 
of CD248 CTLD overexpression in Drosophila S2 cells, under reducing and non-reducing conditions, (b): SDS-PAGE analysis of Drosophila 
derived CD248 CTLD following purification by Ni-NTA chromatography 
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Figure 12. Thermafluor assay with CD248 
CTLD. Melting curves and inverse melting 
temperatures (Tm) from thermafluor assay; 
both  highlighting  buffers  that  exhibited  a 
significant change in thermal shift and Tm, 
compared  to  standard  Tris  NaCl  buffer. 
Table highlighting corresponding optimum 
buffers. 
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4.2.2 Production and crystallisation of CD248 ectodomain. 
 
This section describes the production of soluble CD248 ectodomain in quantities 
sufficient for use in x-ray crystallographic studies. 
 
 
 
The CD248 ectodomain was expressed through the Drosophila system. Western 
blotting analysis revealed the induced expression of CD248 72 hours post induction in 
S2 stable cell lines (seen as a protein band ~38 kDa on western blot, Figure 13A). 
Following Ni-NTA chromatography, the purified protein product was then run on an 
SDS-PAGE gel which revealed successful purification of a band ~ 38 kDa 
corresponding to the full ectodomain, with a few high molecular weight residual 
contaminants (Figure 13B). In an effort to find an optimum buffer for purification, 
storage and crystallisation, a solubility assay was repeated for the full length version. 
 
 
 
Protein was subjected to a further round of gel filtration chromatography using the S200 
column in an effort to obtain higher purity for crystallization. The S200 elution profile 
shows that the protein eluted as a single peak ~220 mL (Figure 13C) SDS page analysis 
of this peak showed successful purification and purity greater than 95% that was 
suitable for crystallization attempts (Fig 13D). 
 
 
 
 
The thermafluor assay highlighted a number of buffers that increased protein stability 
and solubility (Figure 14). The buffer formulation which greatly stabilized CD248 
CTLD was 50 mM Bis-Tris, 150mM NaCl and 10% Glycerol (Tm 65°C), where the 
protein exhibited a 20°C increase in Tm in comparison with the initial storage and 
purification buffer (20 mM Tris, 50mM NaCl pH7.2). 
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Initial crystallization screens were set up following purification by gel filtration 
chromatography, at a relatively moderate concentration of 6 mg/ml in a hanging drop 
format. 1 out of 288 conditions yielded a potential protein hit in structure screen 1 
condition # 19; 0.2M Zinc acetate, 0.1M Na cacodylate pH 6.5 and 18% w/v PEG-8K 
(Figure 15). Low rate of precipitation across many drops was evident which suggests a 
higher concentration of protein (10 + mg/ml) may yield more hits. 
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(d) 
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Figure 13. Expression, purification and SDS page analysis of CD248 ectodomain from a Drosophila S2 cell system. (A) Western blot detection 
of CD248 expression under reducing and non-reducing conditions, at 72 h and 96 h post- induction, using anti-His antibody. (B) SDS-PAGE analysis 
of Drosophila derived CD248 CTLD following purification by Ni-NTA chromatography. (C) size exclusion chromatography elution profile for full 
length CD248 CTLD post Ni-NTA purification using an S200 column. (D) 6S2DS PAGE analysis of CD248 CTLD, following both Ni-NTA and SEC 
purification procedures. 
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Figure 14. Thermafluor assay of CD248 
ectodomain. Melting curves and inverse 
melting  temperatures  (Tm)  from 
thermafluor assay; both highlighting buffers 
that exhibited a significant change in 
thermal shift and Tm, compared to standard 
Tris NaCl buffer. Table highlighting 
corresponding optimum buffers. 
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Figure 15. Initial protein crystal hits of CD248. (A) CD248 Ectodomain protein crystals obtained at 6 mg/ml in structure screen 1 condition # 19; 
0.2M Zinc acetate, 0.1M NA cacodylate pH 6.5 and 18% w/v PEG-8K. (B) CD248 C type lectin domain protein crystals obtained at 11.6 mg/ml in 
Structure screen condition # 2.6 0.1M Nickel chloride hexahydrate, Tris pH 8.5, 1M Lithium Sulphate. (C) 0.01M Zinc sulphate heptahydrate, MES 
pH 6.5, 25% v/v PEG-MME 550. 
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4.3 Conclusions and Discussion 
 
The aim of this chapter was to describe the production of soluble CD248 CTLD and 
entire ectodomain, in quantities sufficient for use in x-ray crystallographic studies. 
Some of the technical issues identified while performing this work will now be 
discussed. 
 
 
 
The CTLD domain of wild type CD248 was originally produced using E. coli expression 
system and in vitro refolding methodologies. However, despite considerable efforts to 
produce soluble homogenous protein, these attempts were largely unsuccessful. 
Although protein was expressed to high levels in the inclusion bodies, the amount and 
identity of the refolded protein was incorrect and inadequate for crystallisation 
purposes. The fact that the protein was expressed at a high rate in the inclusion bodies 
indicates that it was the efficiency of the folding procedure that was the main barrier. 
In an effort to bypass the barrier of chemical refolding, the Drosophila melanogaster 
S2 expression system was used as an alternative and was found to be the more suitable 
expression system for CD248 CTLD protein production. Ni-NTA chromatography was 
used to purify resultant his-tagged proteins. This system was able to produce high yields 
of protein at the required purity, adequate enough for crystallisation screening. This was 
likely due to the efficient post translational modifications processes that take place in 
such cells. 
 
 
 
Once high levels of purified, pure protein were successfully achieved, the next stage was 
then to set up crystallization trials in an attempt to find conditions that may yield protein 
crystals. One problem that became apparent was inherent protein stability issues, 
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in particular reduced solubility at higher protein concentrations. It is common 
knowledge within protein crystallography, that a protein must be homogenous, stable 
and soluble within its buffer for subsequent crystallization trials to be successful. The 
screening of protein buffers using thermal shift assays allowed the identification of 
buffers which increased the melting temperature and overall protein stability of CTLD 
protein in solution. Drosophila-expressed CD248 CTLD protein was used to set up 
crystallisation trials. The hanging drop method yielded 13 potential protein hits, 
whereas the sitting drop method yielded only 8 hits. 
 
 
 
A thermofluor assay was used as an optimization buffer screen for the CD248 CTLD 
protein stability and solubility. The fact that calcium was required in the buffer for 
increased protein stability, solubility and crystal formation suggests that CD248 CTLD 
may require the binding of ionic calcium for protein stability and function. Another key 
issue during crystallization screening was the difficulty differentiating between salt and 
protein crystals within the drops. There are a few different ways of finding out whether 
protein hits are genuine by performing negative protein control plates as well as more 
sophisticated methods such as UV fluorescence protein detection systems. In my case, 
fluorescence protein detection was inconclusive due to practical reasons surrounding the 
plate dimensions, so the hits deemed as genuine protein crystals was based on negative 
protein control plates. Some of the hits produced on small scale are ready susceptible to 
enter optimization and or large scale methods to produce larger crystals adequate 
enough for x-ray diffraction 
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The ectodomain of CD248 protein was produced through the Drosophila S2 system. In 
order to obtain purity high enough for structural studies, the expressed protein required two 
rounds of purification by Ni-NTA then a further round of gel filtration chromatography 
using an S200 column. The screening of protein buffers was performed using thermal 
shift assays which allowed the identification of buffers that increased the melting 
temperature and overall protein stability of ectodomain protein in solution. The presence 
of calcium in the buffer appeared to increase the melting temperature and overall stability 
of CD248 ectodomain in solution, similar to its CTLD, which indicates that it may too 
have an ionic calcium binding function. This observation could perhaps be explained in 
terms of structural features. Both the CTLD and ectodomain contain cysteine residues 
and predicted disulphide bonds, therefore it is a possibility that the severe aggregation 
seen without calcium in the buffer is due to the formation of intermolecular disulphides, 
whereas the presence of calcium stabilizes such bonds. 
 
 
 
Initial crystallisation screening of soluble ectodomain protein (5+ mg/ml) resulted in 1 
potential protein hit. The fact that there was a low rate of precipitation across many of 
the drops suggested that a higher concentration of protein (10 + mg/ml) may yield more 
hits. The initial crystal hit was deemed not good enough for crystallographic analysis and 
require further optimisation and scale up. However, this work provides a good stepping 
stone for determining the x-ray crystallographic structure of CD248 in the future. 
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CHAPTER 5 – CD248 SIGNALLING IN BONE 
FORMATION 
 
 
 
 
5.1 Introduction 
 
As mentioned earlier, CD248 also has a known role in inflammatory disorders. For 
example, (Smith et al. 2011) reported an upregulation of CD248-expressing stromal cells 
and direct association with known determinants of chronic kidney disease (CKD). In 
addition, another study demonstrated an upregulation of CD248-expressing stromal 
fibroblasts within the rheumatoid joint (MacFadyen et al. 2005). Inflammatory 
conditions such as rheumatoid arthritis are characterised by inflammatory-induced focal 
bone loss, which is thought to be due to aberrant osteogenesis. A number of studies 
have linked perturbed osteoblast function to such site-specific bone loss (Gravallese et al. 
1998, Walsh et al. 2009). CD248 is a mesenchymal stem cell (MSC) marker (Bagley et 
al. 2009). MSCs are highly plastic in nature, and have the ability to differentiate into 
adipocytes (fat), chondrocytes (muscle) or osteoblasts (bone). In fact, in silico mining of 
gene expression data (Su et al. 2004) has shown that CD248 is highly expressed on 
osteoblasts. 
 
 
 
The Rheumatology Research Group (RRG) has explored the role of CD248 in bone 
formation in CD248 deficient mice. The following observations have been reported; 
mice deficient in CD248 display increased bone mass, osteoblasts derived from such 
mice display an increased bone mineralisation capacity in vitro, due to an increase in 
osteoblast differentiation (Naylor et al. 2012). 
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However, the molecular mechanism by which CD248 causes such effects was 
unknown. Previous literature highlighting the involvement of CD248 in pericyte 
PDGFR signalling pathways, suggest a similar mechanism in osteoblast function. 
 
 
 
In this chapter, we indeed provide evidence that the PDGF receptor and the MAP kinase 
ERK-1/2 may be involved in the CD248-regulated signalling pathways that control 
osteoblast function and subsequent bone formation. 
 
 
 
5.2 Results 
 
 
5.2.1 CD248 regulates PDGF-BB induced ERK phosphorylation in osteoblasts 
 
Upon PDGFR phosphorylation, multiple intracellular signalling kinases are activated 
such as MAP kinase ERK1/2, leading to the upregulation of the transcription factor 
cFos (Tomkowicz et al. 2010). Therefore, to test whether PDGF signalling was 
perturbed in CD248-deficient mouse osteoblasts, we sought to determine the 
phosphorylation state of ERK1/2 at 0, 1 and 5 minutes post-induction with PDGF-BB. 
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Figure 16. CD248 regulates PDGF-BB induced ERK phosphorylation in 
osteoblasts. Total ERK (t-ERK) and phosphorylated ERK (p-ERK) were assessed by 
Western blotting in osteoblasts from WT and CD248-/- mouse tibiae exposed to PDGF- 
BB for 0, 1, or 5 minutes. 
 
 
 
 
It can be seen from Figure 16, that WT mouse osteoblasts displayed robust ERK-1/2 
phosphorylation 5 minutes post-stimulation with PDGF-BB. However, mouse 
osteoblasts deficient in CD248 exhibited a reduced level of PDGF-BB-induced ERK- 
1/2 phosphorylation at the same time point. It is also important to note that the protein 
levels of total ERK (t-ERK) remained the same across different cells and time-points as 
expected. 
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5.3 Conclusions and Discussion 
 
The aim of this chapter was to determine whether CD248 is required for PDGF 
signalling in osteoblasts, and in turn identify a possible molecular mechanism by which 
CD248 causes its effects on osteoblast differentiation and function. 
 
 
 
Upon induction of osteoblasts with PDGF-BB, CD248 was shown to regulate the 
phosphorylation of the MAPK ERK-1/2. More specifically, the loss of CD248 
expression was shown to disrupt downstream signals originating from the PDGF 
receptor on osteoblasts by reducing the activation of MAPK kinase ERK-1/2. These 
results match previous findings that CD248 is required for PDGF signalling in 
pericyte’s (Tomkowicz et al. 2010). 
 
 
 
Whenever performing western blotting for signalling analysis it is important to be aware 
of some of the inherent limitations surrounding this technique. Examples include 
problems concerning antibody specificity and suboptimal quantitation of protein levels. 
Therefore, additional methods have been used to investigate further and achieve reliable 
evidence in terms of signalling. The Rheumatology Research Group has confirmed 
previous findings that human osteoblasts express PDGFR alpha (Horner et al. 1996, 
Madden et al. 1975). In addition, osteoblasts from wild type mice were shown to exhibit 
12-fold upregulation of cFos (a downstream target of  PDGFR) following post PDFG- 
BB-stimulation, whereas CD248 deficient osteoblasts did not, using Real-time reverse 
transcription–polymerase chain reaction (RT-PCR) (Naylor et al. 2012). 
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These results together demonstrate that CD248 is required for PDGF signalling in 
osteoblasts, which opens up the possibility of the PDGF receptor and the MAP kinase 
ERK-1/2 being directly involved with the CD248-regulated signalling pathways that 
control osteoblast function and subsequent bone formation. 
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CHAPTER 6 – OVERALL DISCUSSION AND FUTURE 
DIRECTIONS 
 
 
 
 
6.1 Overall Discussion 
 
Endosialin (CD248) belongs to an emerging family of cell surface receptors strongly 
linked to cancer and inflammation. CD248 is expressed at high levels during 
embryogenesis, but is absent in normal adult tissue. Interestingly, its expression is 
dramatically upregulated in disease tissue, most notably on a wide range of tumours and 
within the arthritic joint. Functional studies have highlighted an active role in growth, 
metastasis and blood vessel formation. Such effects may relate to the cell-restricted 
nature of CD248 on mesenchymal cell types such as fibroblasts, pericyte’s, osteoblasts 
and mesenchymal stem cells-themselves. Despite such knowledge, little is known about 
the molecular basis of CD248 function and is therefore a high priority in the field. The 
overall aim of this research was to determine the molecular basis of CD248 function. In 
order to achieve this: firstly, CD248 mutants were generated and analysed in growth 
curve assays to define key functional domains, and secondly, soluble CD248 protein 
was expressed, purified and screened for protein crystals. Finally, the role of the CD248 
in the context of osteoblast function and subsequent bone formation was investigated. 
The implications relating to such work will now be discussed. 
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6.1.1 Functional characterisation of CD248 
 
CD248 has a known role in tumour growth, metastasis, wound repair and inflammation. 
Recent evidence suggests that CD248 may cause these effects by increasing the 
proliferation and migration of CD248-expressing stromal cells (Lax et al. 2010). 
Structurally, CD248 is composed of several functional domains; the C-type lectin 
domain (CTLD), the Sushi domain (S) and three EGF repeats (EGF) followed by the 
mucin-like region (MUCIN), the transmembrane section (TM) and the short 
cytoplasmic tail (CYT), (Christian et al. 2001). From a ligand perspective, the 
multidomain architecture of the ectodomain suggests that it may have multiple protein 
partners and in fact in vitro studies suggest that the ectodomain of CD248 may interact 
with numerous extracellular matrix proteins including collagen 1, 4 and fibronectin 
(MacFadyen et al. 2005) as well as a tumour derived ligand Mac-2 BP, commonly 
linked to metastasis (Becker et al. 2008). However, it is not yet known which region of 
the protein is critical for such ligand binding and functional effects. 
 
 
 
The results presented within this thesis indicate that the EGF repeat domain is important 
for the proliferation of CD248-expressing cells. One possibility is that a known or 
unknown ligand may bind directly to the EGF repeat domain of CD248 which may 
activate intracellular signals that result in proliferation effects, possibly through the 
PDGF signalling pathway via upregulation of c-fos. When investigating the domains 
responsible for certain functions it is important to take into consideration other related 
family members. Previous literature has reported similar findings in terms of EGF 
repeats domains being linked to proliferative phenotypes. For example, a study looking 
at the structure and function of a related Group XIV member thrombomodulin, reported 
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that the EGF repeats present in the ectodomain were responsible for the proliferation of 
Swiss 3T3 cells in vitro (Hamada et al. 1995). In addition, the EGF repeat domain of 
coagulation factor XII has also been shown to demonstrate growth-promoting 
phenotypes in Hep G2 cells (Schmeidler-Sapiro et al. 1991). 
 
 
 
Despite the known ligand binding functions of sushi domains in other proteins, the 
results presented within this thesis indicate that the Sushi domain of CD248 is not 
important for the proliferation of MG63 cells. This supports the theory that the sushi 
domain of CD248 does not take part in ligand binding that affects the proliferation of 
CD248-expressing cells. 
 
 
 
The multiple functions exhibited by CD248 likely reflect the multidomain architecture of 
the ectodomain, and it is increasingly likely that that the different domains mediate 
different functions. A good example is thrombomodulin which in addition to its EGF 
mitogen-promoting effects, has also been shown to play an important role in preventing 
leukocytes from binding to the endothelium, via a CTLD-mediated interaction (Conway 
et al. 2002). It is interesting also to note that the most recently discovered Group XIV 
family member, Clec14A, has a known role in angiogenesis as a tumour endothelial 
marker (TEM), more specifically functioning in migration, tube formation and 
endothelial cell-cell adhesion via a CTLD-mediated interaction (Rho et al. 2011), (Mura 
et al. 2012). 
 
 
 
There is growing interest in CD248 not only as a clinical biomarker but as a therapeutic 
target, for which there is a growing need. The current state of knowledge suggests that 
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the interaction between CD248-expressing stromal cells and extracellular matrix 
components represents a good strategy by interfering with the stromal contribution to 
cancer and inflammatory disease. There is currently a drive in the area of designing 
novel therapies which aim to inhibit CD248 in the form of potent blocking antibodies 
and small molecule inhibitors. Previous CD248-targeted antibodies have been directed 
towards the CTLD of CD248 in an effort to inhibit the migratory capacity of CD248- 
expressing cells which are enjoying some success (Tomkowicz et al. 2007). However, 
the findings presented here suggest that the EGF repeat domain may be a good target in 
an attempt to inhibit the proliferation of CD248-expressing cells, at sites of cancer and 
inflammation. 
79 
 
 
 
 
6.1.2 Is Calcium required for CD248 protein stability and function? 
 
CD248 belongs to Group XIV family of C-type lectin proteins, which is a large well 
studied group of metazoan proteins with diverse functions such as adhesion and 
glycoprotein synthesis. The family consists of three other-related proteins; 
thrombomodulin (TBM), complement receptor protein (CD93) (Drickamer and Fadden 
2002), as well as the most recently discovered, C-type lectin domain family member 
 
14A (Clec14A), (Mura et al. 2012). As the classification suggests, they are all 
characterised by a CTLD protruding from the cell surface in addition to a sushi domain, 
epidermal growth factor repeats (EGF) and highly glycosylated mucin-like region. 
However, in spite of the name and classification, the binding of ionic calcium binding to 
CD248 has not been demonstrated. 
 
 
 
It has recently been highlighted that the key amino acids involved in coordinating ionic 
calcium binding are not conserved in CD248, thrombomodulin or CD93 (Valdez et al. 
2012) suggesting that the Group XIV family members do not contain any functional c- 
type lectin activity (Valdez et al. 2012). However, the results presented within this 
thesis contradict such thinking and indicate that ionic calcium binding may be required 
for CD248 structure, stability and function. 
 
 
 
The structural domains that are most likely to require calcium include the CTLD itself 
 
as well as the EGF-repeat domain. Interestingly upon sequence analysis, the EGF-repeat 
domain has a predicted calcium-binding function. It contains not only an EGF-like 
calcium binding conserved site, but also contains an EGF-type aspartate/asparagine 
hydroxylation site (EMBL-EBI database). In fact, the reported thrombomodulin- 
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thrombin interaction is thought to be mediated through the EGF-repeat domain in a 
Ca2+-dependent manner (Sadler et al. 1993). In addition, homologous EGF-repeat 
domains contained within fibrulin-1 have been shown to be responsible for binding of 
fibronectin in a Ca2+-dependent manner also (Tran et al. 1997). 
 
 
 
In addition to the protein ligand binding, there is also a possibility that CD248 could 
bind to carbohydrates in a Ca2+-dependent fashion also. Indeed, the CTLD of selectins 
have been shown to mediate Ca2+-dependent binding of glycosylated receptors on 
heterotypic cells, leading to inflammation and tissue repair (Bischoff 1997). 
 
 
 
The results presented in this thesis may have implications in drug design and targeted 
therapies. When designing receptor antagonists it is important to take into consideration 
the effects of additives. For example, it has been previously reported that the binding of 
monoclonal antibodies to thrombomodulin is Ca2+-dependent, which was manifested by a 
conformational change in the EGF-repeat domain. More specifically it was shown that 
higher concentrations of Ca2+ ions resulted in higher rate of receptor binding (Kimura et 
al. 1989). 
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6.1.3 CD248: a therapeutic target in rheumatoid arthritis 
 
During normal bone development, immature osteoblast cells are recruited to the site of 
bone formation (Maes et al. 2010) whereby they are known to play an active role in 
tissue remodelling and repair. More specifically, they are kept in an immature 
proliferative and pro-migratory state via PDGF signalling and ERK phosphorylation 
(Sanchez-Fernandez et al. 2008) . Another study has shown that the downstream target 
of PDGFR, c-fos (transcription factor) enhances cell cycle progression in osteoblasts, 
further highlighting the role of PDGFR signalling in osteoblast function (Sunters et al. 
2004). Upon differentiation, mature osteoblasts modify their phenotype and become 
mostly non-proliferative and upregulate type 1 collagen (Liu et al. 1997). In certain 
inflammatory disorders such as RA this process is perturbed, and more specifically is 
characterised by inflammation-induced focal bone loss. Within the inflammatory 
microenvironment, osteoclast differentiation is enhanced and osteoblast-mediated bone 
formation is inhibited leading to bone erosion and overall net loss in weight. A number 
of studies have reported a lack of mature osteoblasts at the sites of focal bone erosion in 
RA (Gravallese et al. 1998) and murine inflammatory arthritis (Zwerina et al. 2006) and 
have linked perturbed osteoblast function to site-specific bone loss (Walsh et al. 2009). 
 
 
 
The Rheumatology Research Group (RRG) has explored the role of CD248 in bone 
formation in CD248 deficient mice. The following observations have been reported; 
mice deficient in CD248 display increased bone mass, osteoblasts derived from such 
mice display an increased bone mineralisation capacity in vitro- due to an increase in 
osteoblast differentiation (Naylor et al. 2012). Previous literature highlighting the 
involvement of CD248 in pericyte PDGFR signalling pathways suggested a similar 
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mechanism in osteoblast function. The results reported within this thesis and from the 
group demonstrate that CD248 is required for PDGF signalling in mouse osteoblasts. 
Additional experiments performed within the lab have also shown that this CD248- 
PDGFR signalling interaction was vital for subsequent osteoblast proliferation and 
osteogenesis. Indeed, such studies have shown that the proliferation of PDGF stimulated 
CD248 -/- mouse osteoblasts is significantly reduced and produce more bone nodules 
compared to wild-type osteoblasts (Naylor et al. 2012). 
 
 
 
Although the signalling mechanisms by which CD248 mediates its functions in the past 
have been controversial (Lax et al. 2010), the results within this thesis support previous 
literature from (Tomkowicz et al. 2010), where they showed that the PDGF-BB- 
dependant proliferation of pericyte’s involved the PDGF receptor, subsequent 
phosphorylation of MAP kinase ERK-1/2 and upregulation of the downstream target c- 
fos. Despite this established link, the exact location at which CD248 intersects PDGF 
downstream signalling is still to be determined. It has been previously suggested that 
CD248 may interact directly with and recruit phosphatidylinositol 3 or Src-kinase’s to 
amplify PDGF-BB-induced signals deriving from the PDGF receptor (Valdez et al. 
2012). This hypothesis is supported by the results within this thesis, which highlight that 
the signalling defect is downstream of PDGFR, but upstream of ERK. The small 
cytoplasmic tail has no known kinase function but potential phosphorylation sites may 
interact with intracellular molecules in a direct or indirect-fashion. 
 
 
 
Over the past few years, there has been an interest in targeting the PDGFR-B and 
associated signalling pathway as a useful approach in guided tissue regeneration. The 
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key disadvantage of targeting PDGFR-B is its widespread expression means that the 
functions of many cell types are likely to be affected if inhibited. However, CD248’s 
restricted cell and tissue-specific expression profile at sites of inflammation and 
remodelling, in combination with the results from this thesis and data generated from 
the lab (Naylor et al. 2012) provide evidence that targeting CD248 instead may 
represent a superior approach to targeting tissue regeneration and repair in the context 
of inflammation-associated bone loss. 
 
 
 
 
6.2 Concluding remarks and future directions 
 
In conclusion, work undertaken in this thesis has established a potential role of CD248’s 
EGF-repeat domain in the proliferation of CD248-expressing cells. In addition, 
information regarding the potential calcium-requirement of CD248 has also been 
provided which may aid further structural, ligand and functional studies. Finally, a 
molecular mechanism has been determined which explains the observed effect of 
CD248 in osteoblast function and bone formation, which in combination with other data 
suggests that CD248 may be a strong target for treating inflammation-associated bone 
loss in rheumatoid arthritis patients. Importantly, key reagents and assays have been 
developed which will underpin future studies when examining the structure and 
function of CD248. 
 
 
 
 
An important next step in this field is to elucidate the structure of CD248, specifically 
its ectodomain. Establishing the three dimensional structure of CD248 is essential for 
gaining a comprehensive molecular understanding of CD248 function, and may allow 
the identification of potential ligand binding sites and possibly informing improved anti- 
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stroma therapeutic strategies by directing the design of inhibitors to block CD248 
activity. Another important area of future work will include the identification of novel 
ligands and despite previous literature highlighting the binding of CD248 to 
extracellular matrix proteins, their precise mode of binding has not yet been determined. 
Therefore determining the molecular properties of such ligand interactions remains a 
key aim. 
 
 
 
 
Despite results described within this work, the functional characterization of CD248 
remains to be fully solved. A recent study by Maia et al. (2010) has shown that the 
cytoplasmic tail is required for arthritis progression in mice. Therefore, further studies 
could use mutagenesis techniques to examine the function of the cytoplasmic tail in 
order to identify putative intracellular binding partners and interactions. 
 
 
 
In conclusion, the research described here and associated future research will not only 
improve the basic understanding of CD248 function, but also aid in the design of novel 
blocking inhibitors in the ability to inhibit the stromal contribution to cancer and 
inflammatory disorders. 
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